Developer docs
API playgroundTry for free, no card

Search company profiles

Prolong Pharmaceuticals

Full company profile

uuid000awwy

Namestring
Prolong Pharmaceuticals
Legal namestring
Prolong Pharmaceuticals, LLC
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Prolong Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company founded in 2005 and headquartered in South Plainfield, New Jersey, that develops PEGylated protein therapeutics for ischemia and hypoxia-related conditions. The company's core product is PP-007 (Sanguinate®), a PEGylated carboxyhemoglobin bovine (PCHB) nano-sized oxygen carrier designed as an acellular, dual-action carbon monoxide-releasing and oxygen-transfer agent that selectively oxygenates hypoxic tissue and reduces inflammation. The lead clinical indication is acute ischemic stroke (AIS), with the HEMERA-1 Phase 1/2 trial supporting that program; additional pipeline indications include sickle cell disease vaso-occlusive crisis, cystic fibrosis-related lung inflammation, and hemorrhagic shock/trauma resuscitation.

The company develops its candidates through its proprietary PEGfinity™ platform, which integrates PEGylation chemistry with in-silico analytical methods for protein modification, lead optimization, and structure-function analysis. PEGylation is a well-established drug-delivery modality used in FDA-approved therapies such as Neulasta® and Krystexxa®, and Prolong's founders contributed to the first FDA approval of a PEGylated protein therapeutic (Adagen®, 1990). The company has received FDA Breakthrough Therapy Designation and Fast Track Designation for PP-007 in AIS, and holds patent application WO2024081928 covering a stable hemoglobin protein mixture composition.

Prolong currently generates no commercial revenue: the company operates as a clinical-stage developer, distributing its investigational drug directly to clinical trial sites, and its Expanded Access Policy states it does not provide PP-007 outside of active clinical trials. Upon potential regulatory approval, commercial distribution would flow through hospital pharmacies, specialty pharmacies, and acute-care providers, particularly in stroke treatment settings. The company is backed by two single-family office investors, Avtar Investments and Tarsadia, and is led by CEO Dr. Sandeep Athalye alongside a management team with prior experience at Biocon Biologics, Boehringer Ingelheim, Novartis, Roche, Mylan, Pfizer, and Sandoz.

Short descriptiontext

Prolong Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company developing PEGylated carboxyhemoglobin bovine (PP-007/Sanguinate®) using its proprietary PEGfinity™ platform to treat ischemia and hypoxia in acute ischemic stroke, sickle cell disease, cystic fibrosis, and hemorrhagic shock.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth Plainfield, United States
HQ citystring
South Plainfield
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
PEGylated biologics, oxygen carrier therapeutics, PEGylation drug delivery, biopharmaceutical drug development, ischemia hypoxia treatment
Industry2 codes
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Therapeutics (Oxygen Delivery / Anti-Ischemia)
Social media profiles1 record
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Sanguinate®
Description

PEGylated carboxyhemoglobin bovine (PCHB) product for treating acute ischemic stroke and other conditions of ischemia/hypoxia.

prolongpharma.com
+1 more record
Core offering1 text field

Prolong Pharmaceuticals is developing PP-007 (Sanguinate®), a PEGylated carboxyhemoglobin bovine (PCHB) oxygen carrier built on its proprietary PEGfinity™ platform. PP-007 is an acellular, dual-action carbon monoxide releasing molecule and oxygen transfer agent designed to selectively oxygenate hypoxic tissue, improve perfusion, and reduce inflammation in conditions of ischemia and hypoxia. Lead indications include acute ischemic stroke, sickle cell disease vaso-occlusive crisis, cystic fibrosis, and hemorrhagic shock/trauma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • NIHSS scores at 24 hours: 8.63 for PP-007+MT vs 16.25 for MT only (p<0.05) - statistically significant improvement
+3 more records
Product overview1 text field

Prolong Pharmaceuticals is a clinical-stage biopharmaceutical company with a single core product focus. Their lead biopharmaceutical candidate is PP-007, branded as Sanguinate®, which is developed using the proprietary PEGfinity™ platform technology. PP-007 is a PEGylated carboxyhemoglobin bovine (PCHB) product designed as an oxygen carrier and carbon monoxide releasing molecule for treating conditions of ischemia and hypoxia, with primary development targeting acute ischemic stroke. The PEGfinity™ platform enables the company's PEGylation-based drug development approach for protein therapeutics.

Product and service1 record
1PP-007 (Sanguinate®)
CategoryBiopharmaceutical therapeutic (oxygen delivery / anti-ischemia)
Description

PP-007 (Sanguinate®) is a PEGylated carboxyhemoglobin bovine (PCHB) nano-sized oxygen carrier functioning as an acellular, dual-action carbon monoxide releasing molecule and oxygen transfer agent. It selectively oxygenates hypoxic tissues, improves perfusion, and reduces inflammation, addressing ischemia and hypoxia in acute ischemic stroke, sickle cell disease vaso-occlusive crisis, cystic fibrosis, and hemorrhagic shock/trauma. It is developed for hospital and acute care use and is currently an investigational drug under clinical development.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct indication overlap in acute ischemic stroke with a clinical-stage asset (DM199), making it the most relevant pure-play comparable for AIS commercial modeling.

2Athersys (now Healios)
TypeEmerging player
Description

Developed MultiStem cell therapy for ischemic stroke and ARDS, a directly comparable regenerative/adjunctive approach for acute ischemic stroke at similar clinical stage.

TypeBroad incumbent
Description

Sells the dominant AIS thrombolytic (Activase/alteplase) and is advancing tenecteplase in stroke; represents the standard-of-care incumbent whose behavior shapes PP-007's commercial uptake and clinical positioning.

TypeEmerging player
Description

Clinical-stage stroke biotech developing glenzocimab (anti-GPVI antibody) for acute ischemic stroke, targeting the same thrombectomy-adjunctive use case as PP-007.

TypeBroad incumbent
Description

Established PEGylation platform company (PEGylation chemistry underpinning multiple approved drugs), comparable to Prolong's PEGfinity platform from a technology-and-modality perspective, though focused on small-molecule and polymer conjugates.

TypeEmerging player
Description

Develops levosimendan for cardiovascular indications including cardiogenic shock and PH-HFpEF; comparable oxygen-delivery/hemodynamic-support mechanism and similar clinical-stage profile.

TypeEmerging player
Description

Clinical-stage biopharma developing DM199 (rhKLK1) for acute ischemic stroke, directly overlapping Prolong's lead indication. Prolong's CMO Dr. Kirsten Gruis previously served as CMO at DiaMedica, highlighting comparable stage and therapeutic focus.

8HbO2 Therapeutics
TypeDirect peer
Description

Closest direct peer: also developing a PEGylated hemoglobin-based oxygen carrier (Hemopure-class / Hemoglobin-based Oxygen Carrier) for trauma, ischemia, and sickle cell indications. Competes with Prolong on the same HBOC modality and overlapping indications.

TypeOthers
Description

Biospecimen and clinical-research-services provider supporting biologic and cell-therapy developers; adjacent enabling vendor for clinical-stage biologics programs like PP-007.

TypeDirect peer
Description

Closely affiliated clinical-stage biologics developer led by overlapping management (CEO Dr. Athalye, SVP Pakulski, Head of Ops Dr. Rawal, Director Pandya) with biosimilars and PEGylated biologic programs; provides a structural and operational comparable for Prolong's CMC and regulatory execution.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prolong Pharmaceuticals

Biopharmaceutical Therapeutics (Oxygen Delivery / Anti-Ischemia)prolongpharma.com

Prolong Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company developing PEGylated carboxyhemoglobin bovine (PP-007/Sanguinate®) using its proprietary PEGfinity™ platform to treat ischemia and hypoxia in acute ischemic stroke, sickle cell disease, cystic fibrosis, and hemorrhagic shock.

What Prolong Pharmaceuticals does

Prolong Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company founded in 2005 and headquartered in South Plainfield, New Jersey, that develops PEGylated protein therapeutics for ischemia and hypoxia-related conditions. The company's core product is PP-007 (Sanguinate®), a PEGylated carboxyhemoglobin bovine (PCHB) nano-sized oxygen carrier designed as an acellular, dual-action carbon monoxide-releasing and oxygen-transfer agent that selectively oxygenates hypoxic tissue and reduces inflammation. The lead clinical indication is acute ischemic stroke (AIS), with the HEMERA-1 Phase 1/2 trial supporting that program; additional pipeline indications include sickle cell disease vaso-occlusive crisis, cystic fibrosis-related lung inflammation, and hemorrhagic shock/trauma resuscitation.

The company develops its candidates through its proprietary PEGfinity™ platform, which integrates PEGylation chemistry with in-silico analytical methods for protein modification, lead optimization, and structure-function analysis. PEGylation is a well-established drug-delivery modality used in FDA-approved therapies such as Neulasta® and Krystexxa®, and Prolong's founders contributed to the first FDA approval of a PEGylated protein therapeutic (Adagen®, 1990). The company has received FDA Breakthrough Therapy Designation and Fast Track Designation for PP-007 in AIS, and holds patent application WO2024081928 covering a stable hemoglobin protein mixture composition.

Prolong currently generates no commercial revenue: the company operates as a clinical-stage developer, distributing its investigational drug directly to clinical trial sites, and its Expanded Access Policy states it does not provide PP-007 outside of active clinical trials. Upon potential regulatory approval, commercial distribution would flow through hospital pharmacies, specialty pharmacies, and acute-care providers, particularly in stroke treatment settings. The company is backed by two single-family office investors, Avtar Investments and Tarsadia, and is led by CEO Dr. Sandeep Athalye alongside a management team with prior experience at Biocon Biologics, Boehringer Ingelheim, Novartis, Roche, Mylan, Pfizer, and Sandoz.

Prolong Pharmaceuticals firmographics

Firmographics
Name
Prolong Pharmaceuticals
Legal name
Prolong Pharmaceuticals, LLC
Website
https://prolongpharma.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Prolong Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company developing PEGylated carboxyhemoglobin bovine (PP-007/Sanguinate®) using its proprietary PEGfinity™ platform to treat ischemia and hypoxia in acute ischemic stroke, sickle cell disease, cystic fibrosis, and hemorrhagic shock.
Ownership category
akta.pro rank

Prolong Pharmaceuticals industry classification

Industry
Product category
Biopharmaceutical Therapeutics (Oxygen Delivery / Anti-Ischemia)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • PEGylated biologics
  • Oxygen carrier therapeutics
  • PEGylation drug delivery
  • Biopharmaceutical drug development
  • Ischemia hypoxia treatment

Where Prolong Pharmaceuticals is headquartered

Location

Headquarters

HQ city
South Plainfield
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Prolong Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels4 records

Prolong Pharmaceuticals product offering

Product offering

Core offering

Prolong Pharmaceuticals is developing PP-007 (Sanguinate®), a PEGylated carboxyhemoglobin bovine (PCHB) oxygen carrier built on its proprietary PEGfinity™ platform. PP-007 is an acellular, dual-action carbon monoxide releasing molecule and oxygen transfer agent designed to selectively oxygenate hypoxic tissue, improve perfusion, and reduce inflammation in conditions of ischemia and hypoxia. Lead indications include acute ischemic stroke, sickle cell disease vaso-occlusive crisis, cystic fibrosis, and hemorrhagic shock/trauma.

Product overview

Prolong Pharmaceuticals is a clinical-stage biopharmaceutical company with a single core product focus. Their lead biopharmaceutical candidate is PP-007, branded as Sanguinate®, which is developed using the proprietary PEGfinity™ platform technology. PP-007 is a PEGylated carboxyhemoglobin bovine (PCHB) product designed as an oxygen carrier and carbon monoxide releasing molecule for treating conditions of ischemia and hypoxia, with primary development targeting acute ischemic stroke. The PEGfinity™ platform enables the company's PEGylation-based drug development approach for protein therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

  • Sanguinate®: PEGylated carboxyhemoglobin bovine (PCHB) product for treating acute ischemic stroke and other conditions of ischemia/hypoxia.
  • PEGfinity™

Products and services

  • PP-007 (Sanguinate®) PP-007 (Sanguinate®) is a PEGylated carboxyhemoglobin bovine (PCHB) nano-sized oxygen carrier functioning as an acellular, dual-action carbon monoxide releasing molecule and oxygen transfer agent. It selectively oxygenates hypoxic tissues, improves perfusion, and reduces inflammation, addressing ischemia and hypoxia in acute ischemic stroke, sickle cell disease vaso-occlusive crisis, cystic fibrosis, and hemorrhagic shock/trauma. It is developed for hospital and acute care use and is currently an investigational drug under clinical development.

Quantifiable outcome

  • NIHSS scores at 24 hours: 8.63 for PP-007+MT vs 16.25 for MT only (p<0.05) - statistically significant improvement
  • +3 more outcomes

Companies that use Prolong Pharmaceuticals

Customer profile

Segments4 records

Ideal customer profiles4 records

Prolong Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Prolong Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Prolong Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • DiaMedica Therapeutics: Direct indication overlap in acute ischemic stroke with a clinical-stage asset (DM199), making it the most relevant pure-play comparable for AIS commercial modeling.
  • HbO2 Therapeutics: Closest direct peer: also developing a PEGylated hemoglobin-based oxygen carrier (Hemopure-class / Hemoglobin-based Oxygen Carrier) for trauma, ischemia, and sickle cell indications. Competes with Prolong on the same HBOC modality and overlapping indications.
  • Kashiv Biosciences: Closely affiliated clinical-stage biologics developer led by overlapping management (CEO Dr. Athalye, SVP Pakulski, Head of Ops Dr. Rawal, Director Pandya) with biosimilars and PEGylated biologic programs; provides a structural and operational comparable for Prolong's CMC and regulatory execution.

Emerging players

  • Athersys (now Healios): Developed MultiStem cell therapy for ischemic stroke and ARDS, a directly comparable regenerative/adjunctive approach for acute ischemic stroke at similar clinical stage.
  • Acticor Biotech: Clinical-stage stroke biotech developing glenzocimab (anti-GPVI antibody) for acute ischemic stroke, targeting the same thrombectomy-adjunctive use case as PP-007.
  • Tenax Therapeutics: Develops levosimendan for cardiovascular indications including cardiogenic shock and PH-HFpEF; comparable oxygen-delivery/hemodynamic-support mechanism and similar clinical-stage profile.
  • DiaMedica Therapeutics: Clinical-stage biopharma developing DM199 (rhKLK1) for acute ischemic stroke, directly overlapping Prolong's lead indication. Prolong's CMO Dr. Kirsten Gruis previously served as CMO at DiaMedica, highlighting comparable stage and therapeutic focus.

Broad incumbents

  • Genentech / Roche (Activase/tPA franchise): Sells the dominant AIS thrombolytic (Activase/alteplase) and is advancing tenecteplase in stroke; represents the standard-of-care incumbent whose behavior shapes PP-007's commercial uptake and clinical positioning.
  • Nektar Therapeutics: Established PEGylation platform company (PEGylation chemistry underpinning multiple approved drugs), comparable to Prolong's PEGfinity platform from a technology-and-modality perspective, though focused on small-molecule and polymer conjugates.

Others

  • Sanguine Biosciences: Biospecimen and clinical-research-services provider supporting biologic and cell-therapy developers; adjacent enabling vendor for clinical-stage biologics programs like PP-007.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Prolong Pharmaceuticals social profiles

Digital presence

Prolong Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prolong Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles5 records

Prolong Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prolong Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prolong Pharmaceuticals

What does Prolong Pharmaceuticals do?

Prolong Pharmaceuticals is developing PP-007 (Sanguinate®), a PEGylated carboxyhemoglobin bovine (PCHB) oxygen carrier built on its proprietary PEGfinity™ platform. PP-007 is an acellular, dual-action carbon monoxide releasing molecule and oxygen transfer agent designed to selectively oxygenate hypoxic tissue, improve perfusion, and reduce inflammation in conditions of ischemia and hypoxia. Lead indications include acute ischemic stroke, sickle cell disease vaso-occlusive crisis, cystic fibrosis, and hemorrhagic shock/trauma.

Is Prolong Pharmaceuticals a public or private company?

Prolong Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Prolong Pharmaceuticals founded?

Prolong Pharmaceuticals was founded in 2005. It employs 11 to 50 people.

Where is Prolong Pharmaceuticals based?

Prolong Pharmaceuticals is headquartered in South Plainfield, United States, in the North America region.

Who are Prolong Pharmaceuticals's main competitors?

Direct peers on record are DiaMedica Therapeutics, HbO2 Therapeutics and Kashiv Biosciences. Emerging players are Athersys (now Healios), Acticor Biotech, Tenax Therapeutics and DiaMedica Therapeutics. Broad incumbents are Genentech / Roche (Activase/tPA franchise) and Nektar Therapeutics. Sanguine Biosciences is listed as an others.

Does Prolong Pharmaceuticals have an API?

No public API is recorded for Prolong Pharmaceuticals.

What industry is Prolong Pharmaceuticals in?

Prolong Pharmaceuticals's product category is Biopharmaceutical Therapeutics (Oxygen Delivery / Anti-Ischemia). Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIALAB, Lead Optimization & Preclinical Candidate Selection. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogChronicleBio and Prolong Pharmaceuticals Announce Partnership to Evaluate PP-007 in Myalgic Encephalomyelitis/Chronic Fatigue SyndromeChronicleBio and Prolong Pharmaceuticals announced a development agreement to evaluate PP-007, an oxygen-delivery therapy, for post-exertional malaise in ME/CFS. A planned Phase 2a trial will enroll at least 40 patients, with first dosing anticipated mid-2027. The study will use ChronicleBio's AI platform to identify patients most likely to respond.BioSpaceProlong’s Investigational Therapy for Acute Ischemic Stroke, PP-007, Receives FDA Breakthrough Therapy DesignationProlong Pharmaceuticals announced that its investigational therapy PP-007 received Breakthrough Therapy Designation from the FDA for acute ischemic stroke with anterior large vessel occlusion. The designation builds on Fast Track status and aims to expedite development, with the drug currently under an active IND application.Business Wire BlogProlong’s Investigational Therapy for Acute Ischemic Stroke, PP-007, Receives FDA Breakthrough Therapy DesignationProlong Pharmaceuticals announced that its investigational therapy PP-007 received FDA Breakthrough Therapy Designation for acute ischemic stroke with anterior large vessel occlusion. The designation builds on its existing Fast Track status, and the drug is being evaluated under an active IND application.PharmiWeb.comProlong Pharmaceuticals to Present Phase 1/2 Data from HEMERA-1 for PP-007 in Acute Ischemic Stroke (AIS) at the 2025 World Stroke Conference (WSC)Prolong Pharmaceuticals announced it will present Phase 1/2 clinical data from the HEMERA-1 trial for its investigational drug PP-007 in Acute Ischemic Stroke at the 2025 World Stroke Conference in Barcelona on October 22-24. The trial demonstrated that PP-007 as adjunct to standard care produced a 20% absolute improvement in functional independence and 55% of patients achieved early responder status with rapid neurological recovery. The company is preparing for a global pivotal study (HEMERA-2) following alignment with the FDA, which granted Fast Track Designation for this indication in 2024.Business Wire BlogProlong Pharmaceuticals to Present Preliminary Phase 1 Data from HEMERA-1 for PP-007 in Acute Ischemic Stroke (AIS) at the 2025 International Stroke Conference (ISC)Prolong Pharmaceuticals will present preliminary Phase 1 data from HEMERA-1 for PP-007 in acute ischemic stroke at the 2025 International Stroke Conference. The company completed enrollment for Part 3 and the final DSMB review with no significant safety signals, supporting progression to Phase 3. HEMERA-2, a global Phase 3 trial, is planned.PR NewswireProlong Pharmaceuticals Announces Completion of Enrollment in Phase II Study of SANGUINATE® in the Treatment of Sickle Cell Disease Patients with Vaso-Occlusive Crisis in an Ambulatory SettingProlong Pharmaceuticals announced completion of enrollment in its Phase II study evaluating SANGUINATE® for the treatment of vaso-occlusive crisis in patients with sickle cell disease, with full data expected in the first half of 2018. Preliminary results from a subset of patients presented at the American Society of Hematology annual meeting showed exploratory evidence of an "un-sickling" effect on red blood cells and association with pain scores, while separate animal model data demonstrated improved blood flow and tissue oxygenation. The company plans to consult with the FDA on future clinical development programs for SANGUINATE®.PR NewswireNew Research Suggests SANGUINATE™ Reduces the Number of Sickled Red Blood Cells in Patients with Vaso-Occlusive CrisisProlong Pharmaceuticals announced at the 11th Annual Symposium of the Foundation for Sickle Cell Disease Research that SANGUINATE, its investigational treatment for sickle cell disease, demonstrated effectiveness in reducing sickled red blood cells in patients experiencing vaso-occlusive crisis. Preliminary Phase II trial data from 10 patients showed that SANGUINATE infusion reduced abnormally shaped cells within hours of treatment, with effects sustained at 72 hours post-infusion. The drug, which has received Orphan Drug Designation from the FDA, targets the estimated 70,000 to 80,000 Americans living with sickle cell disease.FinSMEsProlong Pharmaceuticals Raises $30M in FundingProlong Pharmaceuticals, a South Plainfield, New Jersey-based biopharmaceutical company, received a $30M funding commitment from a private investor group. The capital will support research and development and clinical programs for SANGUINATE, a novel oxygen transfer agent. The company plans to develop manufacturing capacity and expand infrastructure for SANGUINATE.